Zeelab Scales Affordable Pharma Play to ₹200 Cr Business

Zeelab Pharmacy is positioning lower price as a core USP rather than a margin concession to build toward a ₹200 Cr revenue base. Healthtech builders should study whether affordability can anchor loyalty and repeat purchase in price-sensitive segments—gross margin compression is offset by unit volume and data moat, but requires relentless operational efficiency.

Source: Inc42 ↗